Summary of Key Points from the Conference Call Industry Overview - The conference call focuses on the **pharmaceutical industry**, particularly the development and investment opportunities in **innovative drugs** and related sectors [1][3][5]. Core Insights and Arguments - **Government Support for Innovative Drugs**: The national policy emphasizes the development of innovative drugs, with various provinces implementing supportive measures, leading to increased market expectations for growth potential in innovative drug companies [1][3][5]. - **Optimized Drug Procurement Policies**: The government has indicated a positive shift in drug procurement policies, which is expected to benefit the generic drug sector and establish a policy bottom for the pharmaceutical industry [1][4]. - **High Pricing of Innovative Drugs**: The pricing of innovative drugs should align with their clinical value, promoting compliance in their use within hospitals and enhancing the commercialization of clinically valuable drugs [1][7]. - **Market Potential for GLP-1 Drugs**: The GLP-1 weight loss drug market is projected to exceed **$200 billion**, with significant opportunities in the supply chain, particularly for domestic companies in the GLP-1 receptor agonist sector [1][8][9]. - **Investment Opportunities in Chemical Reagents**: The synthesis of drugs requires substantial chemical reagents and raw materials, presenting investment opportunities in leading companies that are expected to see clear performance and valuation growth over the next 3 to 5 years [1][10]. Additional Important Content - **Impact of Medical Reform**: Future medical reforms will continue to drive both incremental innovation and optimization of existing products, enhancing the overall quality and compliance of the pharmaceutical industry [6][12]. - **Geopolitical Risks**: The geopolitical landscape may create volatility in stock prices, but domestic companies in the GLP-1 sector are well-positioned due to their strong production capabilities [9][11]. - **AI in Healthcare**: The integration of AI in healthcare is seen as a slow variable that will enhance efficiency in drug development, although its immediate impact on profitability is limited [13][14]. - **Consumer Market Dynamics**: The pharmaceutical sector is characterized by rigid demand, with growth opportunities in outpatient self-pay markets and specific segments like ophthalmology and aesthetic medicine [16][19]. - **Valuation Recovery**: The recovery of valuations in the pharmaceutical sector is contingent on improvements in the macroeconomic environment, with a focus on segments that can command brand premiums [18][19]. This summary encapsulates the key points discussed in the conference call, highlighting the current state and future prospects of the pharmaceutical industry, particularly in the context of innovative drugs and market dynamics.

Group 1: Liquidity and Performance of Sci-Tech Pharmaceutical Index ETF - The Sci-Tech Pharmaceutical Index ETF had a turnover rate of 16.48% during the trading session, with a transaction volume of 37.98 million yuan, indicating active market trading [2] - Over the past week, the average daily transaction volume of the ETF reached 48.92 million yuan, ranking first among comparable funds [2] - In the past year, the ETF's scale increased by 154 million yuan, achieving significant growth and ranking first in new scale among comparable funds [2] - The ETF's shares grew by 130 million units in the past year, also ranking first in new shares among comparable funds [2] - As of June 10, the net value of the ETF increased by 25.51% over the past year [2] - The highest monthly return since inception was 23.29%, with the longest consecutive monthly gains being 4 months and a maximum increase of 21.76% [2] - The average monthly return during the rising months was 8.18%, with a historical one-year profit probability of 69.81% [2] Group 2: Market Trends and Investment Opportunities - The Central Committee of the Communist Party of China and the State Council issued opinions to improve the basic medical insurance drug catalog adjustment mechanism and to develop a commercial health insurance innovative drug catalog [3] - A report from Dongwu Securities indicated that there were 73 oral presentations from China at the 2025 ASCO, marking a historical high, with 89 out of 184 ADC pipeline studies coming from China, accounting for approximately 48.4% of the total [3] - The agency believes that the competitiveness of domestic innovative drugs in the global market is continuously improving, and international investors' confidence in Chinese innovative drug companies is increasing [3] - Domestic innovative drugs are transitioning from "catching up" to "leading," presenting significant investment opportunities [3] - Investors without stock accounts can access the Sci-Tech Biopharmaceutical ETF linked fund (021061) to capitalize on opportunities in the Sci-Tech Board biopharmaceutical sector [3]

Group 1 - As of June 9, the margin balance in the Shanghai, Shenzhen, and Beijing markets reached 1,816.127 billion yuan, marking a new high since April 16 [1] - The financing balance was 1,798.283 billion yuan, an increase of 1.118 billion yuan compared to April 16 [1] - The increase in margin balance indicates heightened market activity and investor willingness to engage in credit trading [3] Group 2 - From April 16 to June 9, 217 companies received net financing purchases exceeding 100 million yuan, with automotive companies being particularly favored [2] - BYD, Seres Group, and Anhui Jianghuai Automobile Group received net financing purchases of 2.934 billion yuan, 1.212 billion yuan, and 1.061 billion yuan, respectively [2] - The strong interest in automotive companies reflects the positive development prospects of the new energy vehicle industry [2] Group 3 - Companies favored by financing clients are primarily in the automotive parts, chemical pharmaceuticals, and communication equipment sectors, with 18, 10, and 10 companies respectively [4] - The rapid growth in new energy vehicle sales benefits automotive parts companies, which are crucial to the automotive industry [4] - Among the 217 companies, 148 reported year-on-year growth in net profit attributable to shareholders in Q1, accounting for 68.20% [4]

Core Viewpoint - The Chinese innovative drug sector is experiencing a resurgence, driven by recent approvals of new drugs, increased market activity, and favorable policy changes, indicating a new growth cycle for the industry [1][2][16]. Group 1: Market Activity - On May 29, the National Medical Products Administration approved 11 innovative drugs, with 10 from listed companies, leading to a surge in stock prices and significant market interest [1]. - Following the approvals, 53 stocks hit the daily limit up in the A-share market, and over 200 million yuan flowed into innovative drug ETFs in Hong Kong over the past 20 trading days [1][2]. - The innovative drug sector, which had been quiet for two years, is now seeing renewed interest from investors, with venture capitalists starting to push more projects for investment decisions [2]. Group 2: Funding Trends - The first quarter of 2025 saw over 20 billion yuan in financing for the innovative drug sector, with at least 19 financing events occurring, indicating a robust recovery in investment [3][4][5]. - Major financing rounds included significant investments in companies focusing on various therapeutic areas, including immunotherapy and gene therapy, showcasing a diverse interest from capital [4]. Group 3: Product Development - In the first five months of this year, over 20 class 1 innovative drugs were approved, marking a record for the past five years [6][7]. - The approval rate for new drugs has significantly increased since the implementation of the new drug registration management measures in 2020, with approvals rising from single digits in previous years to over 30 in recent years [8]. Group 4: Policy Environment - The regulatory environment for innovative drugs in China is continuously improving, with recent reforms aligning more closely with international standards, enhancing the credibility of clinical trial data [11][12]. - The government has implemented a comprehensive support system for innovative drugs, including payment reforms and a multi-layered insurance system, which is expected to facilitate market access and improve commercialization prospects [13][14][15]. Group 5: Future Outlook - The innovative drug sector is poised for a new growth cycle, supported by clinical breakthroughs, international collaborations, and favorable policies, indicating a potential "golden period" for the industry [16].

Market Overview - The Shanghai Composite Index fell by 0.44% on June 10, with six industries experiencing gains, led by beauty care and banking, which rose by 1.10% and 0.48% respectively. The pharmaceutical and biotechnology sector ranked third in terms of gains [1] - The defense and military industry and the computer sector saw the largest declines, with drops of 1.97% and 1.87% respectively [1] Capital Flow Analysis - The main capital outflow from the two markets totaled 45.141 billion yuan, with five industries seeing net inflows. The banking sector led with a net inflow of 871 million yuan, while the public utilities sector had a slight decline of 0.04% and a net inflow of 822 million yuan [1] - A total of 26 industries experienced net capital outflows, with the electronics sector leading at 7.532 billion yuan, followed by the computer sector with 7.427 billion yuan. Other sectors with significant outflows included telecommunications, defense and military, and machinery equipment [1] Pharmaceutical and Biotechnology Sector - The pharmaceutical and biotechnology sector rose by 0.33%, despite a net capital outflow of 1.883 billion yuan. Out of 475 stocks in this sector, 196 rose, with 12 hitting the daily limit, while 265 fell, including one hitting the lower limit [2] - The stocks with the highest net inflows included Harbin Sanlian with 274 million yuan, followed by Saili Medical and Huahai Pharmaceutical with 225 million yuan and 202 million yuan respectively [2] - The sector's outflow leaderboard featured Changshan Pharmaceutical with a net outflow of 351 million yuan, followed by Hanyu Pharmaceutical and Ruizhi Pharmaceutical with outflows of 295 million yuan and 182 million yuan respectively [4]

Group 1 - Beijing's computing power supply exceeded 33,000 PetaFLOPS in Q1 2023, expected to surpass 45,000 PetaFLOPS by the end of the year, indicating a significant development in the city's digital economy infrastructure [1] - The implementation plans for computing infrastructure and optimization of existing data centers from 2024 to 2027 focus on building four public intelligent computing centers in Haidian, Chaoyang, Yizhuang, and western Beijing [1] - The A-share market saw a rebound on June 10, with AI-related stocks experiencing a correction, while some stocks like Zhongyou Technology and Chip Origin rose over 2% [1] Group 2 - The AI sector is experiencing unprecedented growth opportunities, with global tech giants and leading domestic companies increasing investments to advance Agent technology [2] - Major international companies such as Microsoft, Google, Anthropic, and OpenAI are set to release next-generation AI products by May 2025, marking a transition from auxiliary tools to autonomous generation and deep integration into business processes [2]

Core Viewpoint - Invesco Great Wall Fund announced the resignation of Chairman Li Jin due to the expiration of his term, with General Manager Kang Le taking over the role temporarily for a period not exceeding six months [2] Group 1: Management Changes - Li Jin's resignation was effective on May 29, 2025, after serving as Chairman since September 2020 [3] - Prior to his role at Invesco Great Wall Fund, Li Jin held various senior positions in companies such as China Huaneng Group and Yongcheng Property Insurance [3] Group 2: Fund Performance - Invesco Great Wall Fund has experienced a continuous decline in performance from 2022 to 2024, with revenues of 4.234 billion, 3.83 billion, and 3.373 billion yuan, reflecting year-on-year decreases of 6.34%, 9.53%, and 11.93% respectively [3] - Net profits during the same period were 1.368 billion, 1.175 billion, and 951 million yuan, with year-on-year declines of 2.46%, 14.05%, and 19.09% respectively [3] Group 3: Specific Fund Analysis - The performance of the Invesco Great Wall Jingli Growth Mixed Fund has drawn market attention, with a net value decline of 27.61% since its inception on May 7, 2021, and a 12.61% drop over the past year [4][5] - As of June 4, 2025, the fund's A-class share had a net value of 0.7238, with recent performance showing declines of 2.18% over the past month and 21.99% over the past six months [5] - The fund's A-class shares have underperformed their benchmark by 21.85 percentage points since inception, with 93.32% of total assets allocated to stocks and no bonds held [6]

Core Viewpoint - The pharmaceutical sector in both A-shares and Hong Kong has shown significant performance, with innovative drug stocks being a key driver of growth, particularly due to external licensing transactions and favorable policies supporting the industry [4][13]. Group 1: Market Performance - The A-share pharmaceutical and biotechnology sector rose by 1.13%, ranking 17th among 31 industries [4]. - In the Hong Kong market, the healthcare index increased by 4.11%, and the biotechnology index rose by 4.52%, outperforming the Hang Seng Index, which gained 2.16% [4]. - The innovative drug sector has seen a substantial increase in external licensing transactions, with a total of $45.5 billion in transactions from January to May 2025, accounting for over 30% of the global total [4][5]. Group 2: Company Developments - The company reported potential transactions that could yield up to $5 billion in upfront and milestone payments, with one transaction expected to complete by June [5]. - The innovative drug sector has been active since a record licensing deal by a major pharmaceutical company on May 20, which has led to increased activity in the sector [4]. Group 3: ETF and Fund Performance - The largest pharmaceutical ETFs in China include the Huabao Medical ETF with a size of 25.9 billion yuan and the E Fund Medical ETF with 20.8 billion yuan, with respective year-to-date gains of 0.92% and 3.32% [9][11]. - The largest innovative drug ETFs are the GF Fund Hong Kong Innovative Drug ETF, the Yinhua Fund Innovative Drug ETF, and the Bosera Fund Hang Seng Medical ETF, with sizes of 9.889 billion yuan, 9.662 billion yuan, and 8.436 billion yuan respectively [9][11]. Group 4: Future Outlook - The innovative drug sector is expected to maintain its growth momentum, driven by policy support, global competitiveness, and the realization of commercial profits [13]. - The demand for innovative drugs is anticipated to recover by 2025, with improvements expected in the medical services and OTC sectors [13].

Core Viewpoint - The article analyzes the investment strategies and decision-making processes of successful fund managers in China, highlighting their ability to learn from mistakes and adapt their investment approaches to enhance future portfolio returns [1]. Group 1: Zhao Xiaodong and Guohai Franklin Fund - Zhao Xiaodong has 21 years of experience in the securities industry and 15 years in public fund management, focusing on sectors like finance, food and beverage, and automotive, while also identifying opportunities in emerging trends like renewable energy and TMT [3]. - Under Zhao's management, the Guofu Small and Medium Cap Stock Fund achieved an annualized return of 10.9% from November 2010 to April 2025, outperforming the CSI 300 Index by 9.55% [3]. - Zhao reduced exposure to high-valuation sectors like food and beverage and biomedicine in 2020, decreasing the food and beverage sector's allocation from 18.53% to 5.98% and biomedicine from 11.20% to 5.68% [4][5]. - He strategically increased allocations to the banking sector, raising its share from 16.34% in mid-2020 to 27.31% by mid-2023, reflecting confidence in the sector's valuation and growth potential [6]. Group 2: Investment Lessons from Aimeike - Zhao's investment in Aimeike, which saw a 50.76% decline from June 2022 to December 2023, highlighted the risks of over-relying on historical growth data without considering industry dynamics [7][8]. - The initial investment was based on Aimeike's strong growth metrics, but subsequent market changes and increased competition led to a reassessment of the company's growth potential and valuation [8]. - This experience prompted Zhao to refine his investment process, emphasizing the need for dynamic assessments of industry conditions and company fundamentals [8]. Group 3: Yang Jiawen and E Fund - Yang Jiawen, with 13 years of experience, initially focused on consumer sectors but expanded his investment scope to include manufacturing and TMT, demonstrating a diverse investment perspective [11]. - In 2023, Yang underestimated the value of dividend stocks, leading to underperformance in his fund as the market shifted towards high-dividend assets amid economic uncertainty [12][14]. - Yang's subsequent adjustments in 2024 involved increasing allocations to high-dividend stocks, reflecting a more balanced investment approach that considers both growth and value [14][15]. Group 4: Gu Xuan and Bond Fund Management - Gu Xuan, with 19 years of experience, emphasizes a balanced approach to fixed income, focusing on credit bonds while managing interest rate risks through macroeconomic analysis [20][21]. - His management faced challenges during the pandemic, leading to a reassessment of strategies to better align with changing monetary policies and market conditions [24][25]. - Gu's adjustments in 2024 demonstrated a refined understanding of market dynamics, successfully navigating interest rate fluctuations and enhancing the fund's risk management capabilities [26][27].

[Table_Reportdate] 2025年06月04日 ➢ 1.创新药密集上市，关注后续医保谈判————医药生物行业周报（2025/05/26- 2025/06/01） ➢ 2.供给端扰动背景下，关注相关化工板块配置机会——基础化工行业周报（2025/05/26- 2025/06/01） ➢ 3.白酒持续筑底，重视新消费趋势——食品饮料行业周报（2025/5/26-2025/6/1） ➢ 4.轨交设备板块业绩改善，关注后续铁路固定资产投资进展——机械设备行业周报 （20250526-20250601） 张季恺 S0630521110001 zjk@longone.com.cn 证券分析师： 王洋 S0630513040002 wangyang@longone.com.cn 证券分析师： 刘思佳 S0630516080002 liusj@longone.com.cn 联系人： 花雨欣 hyx@longone.com.cn [晨会纪要 Table_NewTitle] 20250604 重点推荐 财经要闻 晨 会 纪 要 证券研究报告 HTTP://WWW.LONGONE.COM.CN 请务必仔细阅读正文后的 ...